Mechanism of Action
CCK2 Receptor Signaling
Gastrin binds CCK2 receptors (identical to brain CCK-B receptors) on enterochromaffin-like (ECL) cells, stimulating histamine release, which then acts on H2 receptors on parietal cells to drive HCl secretion. Direct CCK2 receptor activation on parietal cells contributes approximately 30% of acid stimulation. Gastrin also directly activates chief cells for pepsinogen secretion and is a major trophic factor for the gastric mucosa.
Gastrinoma and Hypergastrinemia
Zollinger-Ellison syndrome results from gastrin-secreting tumors (gastrinomas) causing massive acid hypersecretion and refractory peptic ulcers. Understanding gastrin physiology underpins proton pump inhibitor therapy (PPIs) -- by reducing luminal acid, PPIs remove the normal acid-inhibition feedback, causing compensatory hypergastrinemia with chronic PPI use. Elevated gastrin may drive gastric carcinoid formation over time.
Research Summary
Diagnostic Applications
Historical/CurrentPentagastrin stimulation test historically used to measure maximal acid output (gastric physiology, ulcer diagnosis). Pentagastrin was more recently used to stimulate calcitonin release for screening and follow-up of medullary thyroid carcinoma (MTC). The pentagastrin stimulation test for MTC has been largely replaced by calcium gluconate stimulation or ultrasensitive calcitonin assays.
Cancer and Anti-Gastrin Therapy
Active ResearchCCK2 receptors are overexpressed in many gastrointestinal and pancreatic cancers. Anti-gastrin immunotherapy (Gastrimmune/polyclonal antibody approach) and gastrin receptor antagonists (netazepide) are in clinical trials for gastric cancer, Barrett esophagus, and type 1 gastric carcinoids. Gastrin-stimulated trophic effects may promote carcinogenesis in chronic hypergastrinemia.
Calculate your Gastrin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Gastric acid secretion testing (historical) | Pentagastrin 6 mcg/kg SC; measure gastric acid output at 15-60 min | Single diagnostic dose | Subcutaneous |
| MTC calcitonin stimulation (historical) | Pentagastrin 0.5 mcg/kg IV over 5 seconds; measure calcitonin at 0, 1, 2, 5 min | Single diagnostic dose | Intravenous |
Pentagastrin has been discontinued in many countries. Calcium gluconate stimulation test has replaced pentagastrin for calcitonin testing in most centers.
Interactions
Safety Profile
Pentagastrin SC/IV causes nausea, abdominal pain, urgency, dizziness, and flushing -- similar to CCK. Hypotension and tachycardia at higher doses. Contraindicated in active gastrointestinal bleeding and acute pancreatitis. Endogenous gastrin does not cause adverse effects at physiological levels; pathological hypergastrinemia (Zollinger-Ellison) causes symptoms via excessive acid production rather than direct hormone toxicity. Pentagastrin manufacture has been discontinued in major markets; alternatives are now standard of care for former indications.
References
- [1]Gregory RA, Tracy HJ. The constitution and properties of two gastrins extracted from hog antral mucosa. Gut. 1964;5:103-117.
- [2]Dockray GJ. Gastrin and gastric acid secretion. Physiol Rev. 2009;89(4):1459-1496.